High rate of Ki-67 increase in entero-pancreatic NET relapses after surgery with curative intent
Authors
Merola, E.Perren, A.
Rinke, A.
Zerbi, A.
McNamara, Mairead G
Arsenic, R.
Fazio, N.
de Herder, W.
Valle, Juan W
Gress, T. M.
Wiedenmann, B.
Pascher, A.
Pavel, M. E.
Affiliation
Department of Medicine 1, Division of Endocrinology, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, GermanyIssue Date
2022
Metadata
Show full item recordAbstract
Neuroendocrine neoplasms (NENs) present with advanced disease at diagnosis in up to 28% of cases, precluding the possibility of curative-intent surgery. Histopathological heterogeneity of this disease can be observed inter-individually as well as intra-individually during disease course. The present study aimed to assess the frequency of Ki-67 change after radical surgery, in a series of patients with radically resected entero-pancreatic neuroendocrine tumors (EP-NETs). We present the analysis of a multicenter, retrospective, series of EP-NETs G1-G2 recurring after radical resection and with histological re-evaluation at disease recurrence (DR). The primary endpoint was the description of Ki-67 change at DR compared to time of surgery. The secondary endpoint was assessment of recurrence-free survival (RFS) rates. In total, 47 patients had a second histological evaluation and could be included in the present study. Median Ki-67 at surgery was 3% (range 1-15%) but, at DR, a significant increase in the value was observed (7%, range 1-30%; p < .01) and involved 66.0% of cases, with a corresponding increase in tumor grading in 34.0% (p = .05). Median RFS of the overall population was 40 months, and was worse when Ki-67 increased at DR vs. stable Ki-67 value (36 vs. 61 months, respectively; p = .02). In conclusion, in more than half of the cases with relapse after radical surgery, a higher proliferative index with a potentially more aggressive potential was observed. Therefore, histological reassessment should be considered on DR because tailored therapeutic strategies may be required for these patients.Citation
Merola E, Perren A, Rinke A, Zerbi A, McNamara MG, Arsenic R, et al. High rate of Ki-67 increase in entero-pancreatic NET relapses after surgery with curative intent. Journal of neuroendocrinology. 2022 Oct;34(10):e13193. PubMed PMID: 36306194. Epub 2022/10/29. eng.Journal
Journal of NeuroendocrinologyDOI
10.1111/jne.13193PubMed ID
36306194Additional Links
https://dx.doi.org/10.1111/jne.13193Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1111/jne.13193
Scopus Count
Collections
Related articles
- Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms?
- Authors: Merola E, Rinke A, Partelli S, Gress TM, Andreasi V, Kollár A, Perren A, Christ E, Panzuto F, Pascher A, Jann H, Arsenic R, Cremer B, Kaemmerer D, Kump P, Lipp RW, Agaimy A, Wiedenmann B, Falconi M, Pavel ME
- Issue date: 2020 May
- Radical Resection in Entero-Pancreatic Neuroendocrine Tumors: Recurrence-Free Survival Rate and Definition of a Risk Score for Recurrence.
- Authors: Merola E, Pascher A, Rinke A, Bartsch DK, Zerbi A, Nappo G, Carnaghi C, Ciola M, McNamara MG, Zandee W, Bertani E, Marcucci S, Modica R, Grützmann R, Fazio N, de Herder W, Valle JW, Gress TM, Fave GD, de Pretis G, Perren A, Wiedenmann B, Pavel ME
- Issue date: 2022 Sep
- Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors: Improving Its Prognostic Value for Recurrence of Disease.
- Authors: Lopez-Aguiar AG, Ethun CG, Postlewait LM, Zhelnin K, Krasinskas A, El-Rayes BF, Russell MC, Sarmiento JM, Kooby DA, Staley CA, Maithel SK, Cardona K
- Issue date: 2018 Jan
- Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
- Authors: Nuñez-Valdovinos B, Carmona-Bayonas A, Jimenez-Fonseca P, Capdevila J, Castaño-Pascual Á, Benavent M, Pi Barrio JJ, Teule A, Alonso V, Custodio A, Marazuela M, Segura Á, Beguiristain A, Llanos M, Martinez Del Prado MP, Diaz-Perez JA, Castellano D, Sevilla I, Lopez C, Alonso T, Garcia-Carbonero R
- Issue date: 2018 Apr
- HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
- Authors: Gamboa AC, Ethun CG, Postlewait LM, Lopez-Aguiar AG, Zhelnin K, Krasinskas A, El-Rayes BF, Russell MC, Kooby DA, Staley CA, Cardona K, Maithel SK
- Issue date: 2020 Dec